selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The company’s most advanced drug candidate, si-544, is a best-in-class Kv1.3 blocker for the treatment of autoimmune diseases.
Investors 1
| Date | Name | Website |
| 16.07.2020 | Global Sou... | globalsour... |
Mentions in press and media 3
| Date | Title | Description |
| 11.03.2021 | Here’s how Amsterdam’s The Selection Lab combats biases in the recruitment process; raises €300K | Amsterdam-based The Selection Lab, a startup that offers validated assessments to select the best possible candidates for a job, has secured €300K in a fresh round of funding from Arches Capital. “In the upcoming 18 months we expect to grow... |
| 04.02.2020 | Clinical study site selection platform closes $14M Series A | |
| - | selectION | “Home - SelectION, Inc.” |